Capricor Therapeutics Reports First Quarter 2021 Financial Results and Provides Corporate Update
May 13, 2021 16:05 ET | Source: Capricor Therapeutics Capricor Therapeutics
-Data for Phase II INSPIRE Clinical Trial Expected in Third Quarter-
-Plan to File IND for Multivalent Exosome-mRNA Vaccine for SARS-CoV-2 in Third Quarter-
-To Host Conference Call and Webcast Today at 4:30 p.m. ET-
LOS ANGELES, May 13, 2021 (GLOBE NEWSWIRE) Capricor Therapeutics (NASDAQ: CAPR), a biotechnology company focused on the development of transformative cell- and exosome-based therapeutics for the treatment and prevention of a broad spectrum of diseases, today reported its financial results for the first quarter ended March 31, 2021, and provided an overview of its recent operational highlights. Management will host a webcast and conference call at 4:30 p.m. today after market.
Allogene Therapeutics Receives IND Clearance from the U S Food and Drug Administration for ALLO-715 in Combination with Nirogacestat in Relapsed/Refractory Multiple Myeloma – IT Business Net itbusinessnet.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from itbusinessnet.com Daily Mail and Mail on Sunday newspapers.